Modality
Peptide
MOA
SGLT2i
Target
PCSK9
Pathway
NF-κB
MS
Development Pipeline
Preclinical
~Oct 2020
→ ~Jan 2022
Phase 1
~Apr 2022
→ ~Jul 2023
Phase 2
Oct 2023
→ Jun 2025
Phase 2Current
NCT05804048
1,790 pts·MS
2023-10→2025-06·Not yet recruiting
1,790 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-199mo agoPh3 Readout· MS
Trial Timeline
Q42024Q2Q3Q42025Q2Q3
P2/3
Not yet…
Catalysts
Ph3 Readout
2025-06-19 · 9mo ago
MS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05804048 | Phase 2/3 | MS | Not yet recr... | 1790 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 |